Single Domain Antibodies Against Cll-1



Roy Lobb, Paul Rennert


  1. Aleta Biotherapeutics Inc.


Antibodies that specifically bind to CLL-1 are described, as well as methods of making and using such antibodies. In one aspect, the present disclosure provides, among other things, antibodies, or antigen binding fragments thereof, that bind (e.g., selectively bind) CLL-1, compositions useful for binding CLL-1, and methods for treating disease comprising administration of such antibodies, or antigen binding fragments thereof.

CovalX Technology Used

Epitope Mapping

Contact our Scientific Team to Start the Conversation

Request A Call
Categories : Patents, Epitope Mapping